search

Active clinical trials for "Bone Diseases, Metabolic"

Results 111-120 of 355

Zoledronate for Osteopenia in Pediatric Crohn's

Crohn's DiseaseOsteopenia1 more

Background: Up to 30% of children and adolescents with Crohn's disease have decreased bone strength, or decrease bone density, called osteopenia. Bisphosphonates are a group of drugs that have been well studied and found to be effective in the treatment of osteopenia in menopausal women. Zoledronate is a very potent third generation bisphosphonate, that is safe and easy to administer, and has been found effective in the treatment of menopausal women with osteopenia. Hypothesis: The investigators hypothesize that zoledronate can improve bone density in children and adolescents with Crohn's disease with osteopenia.

Completed9 enrollment criteria

A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women

Osteopenia

The primary objective of this study is to determine the safety and tolerability of AMG 167 following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.

Completed36 enrollment criteria

The Effects of Potassium Citrate on Bone Metabolism

Bone DiseasesMetabolic2 more

Skeletal buffering of chronic acid loads may contribute to a significant amount of bone loss over time. Evidence from a few small short-term studies suggests that basic compounds, namely potassium citrate and potassium bicarbonate may reduce bone loss and improve bone density. The purpose of this study is to evaluate the effects of potassium citrate on bone metabolism. We hypothesize that administration of potassium citrate to postmenopausal women with osteopenia will reduce bone resorption and improve bone mineral density. Postmenopausal women with osteopenia (T score between -1.0 and -2.5) and no history of fracture will be randomized to either daily potassium citrate or placebo for one year. Primary outcomes will be markers of bone turnover, which will be measured over 12 months. Secondary outcomes will be bone mineral density, compliance, and adverse events.

Completed12 enrollment criteria

A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab...

Low Bone Mineral DensityOsteopenia1 more

The purpose of this study is to compare the immunogenicity profiles of denosumab pre-filled syringe (PFS) and vial at 6 months in postmenopausal women with low bone mineral density (BMD).

Completed15 enrollment criteria

A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment...

Postmenopausal Osteoporosis

This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.

Completed5 enrollment criteria

Alendronate Osteoporosis Study

Glucocorticoid-Associated Osteopenia and Osteoporosis

This trial will test the hypothesis that among 20 children and adolescents from Children's Hospital, Boston with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease and vasculitis, treatment of glucocorticoid-associated osteopenia and osteoporosis with 18 months of alendronate (FOSAMAX®, Merck & Co., Inc.) will result in greater improvement in the mean change of individual AP spine bone mineral density (BMD) (gm/cm2) determined by dual energy X-ray absorptiometry (DXA) than treatment with 18 months of standard of care therapy.

Completed22 enrollment criteria

Adding Phosphorus to Osteoporosis Drug Treatment

OsteoporosisOsteopenia

Osteoporosis causes bones to weaken and break more easily. Calcium and phosphorus are two minerals that are essential for normal bone formation. Unfortunately, calcium salts commonly prescribed in anti-osteoporosis treatment bind phosphorus from food and restrict phosphorus available for bone building. Teriparatide is a drug that reduces the risk of fractures by increasing bone thickness and strength. Vitamin D is also necessary for strong bones and teeth. The purpose of this study is to evaluate the bone-building effectiveness of two calcium supplements, one with a source of phosphorus and one without, in combination with teriparatide and vitamin D in women with osteoporosis.

Completed12 enrollment criteria

Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients

Cystic FibrosisOsteoporosis2 more

The primary objective of this study is to determine efficacy of 70 mg alendronate once weekly compared to placebo. This will be measured by percent changes in lumbar spine(LS) bone mineral density(BMD) in adult cystic fibrosis(CF)patients after one year of treatment. The investigators hypothesize that in adult CF patients with osteopenia or osteoporosis, alendronate 70 mg once weekly will produce a mean increase from baseline in lumbar spine BMD that is greater than that observed with placebo at 12 months.

Completed20 enrollment criteria

Texture Analysis for Postmenopausal Osteoporosis

OsteoporosisOsteopenia

The purpose of this study is to determine if a new test for osteoporosis can be useful in monitoring treatment. We are studying a new method for examining the quality of bone by an experimental method of computerized analysis of radiographic images (x-ray pictures) of the heel.

Completed6 enrollment criteria

Once Weekly Parathyroid Hormone for Osteoporosis

OsteopeniaOsteoporosis

Daily parathyroid hormone (PTH) is approved by the FDA for the treatment of osteoporosis. This study will evaluate the safety and effectiveness of PTH when given once a week.

Completed6 enrollment criteria
1...111213...36

Need Help? Contact our team!


We'll reach out to this number within 24 hrs